Last reviewed · How we verify

Metamizole Sodium

Insel Gruppe AG, University Hospital Bern · FDA-approved active Small molecule

Metamizole sodium inhibits prostaglandin synthesis by blocking cyclooxygenase enzymes, reducing pain, fever, and inflammation.

Metamizole sodium inhibits prostaglandin synthesis by blocking cyclooxygenase enzymes, reducing pain, fever, and inflammation. Used for Acute pain (postoperative, traumatic, or other acute pain conditions), Fever, Chronic pain conditions.

At a glance

Generic nameMetamizole Sodium
Also known asMetamizole
SponsorInsel Gruppe AG, University Hospital Bern
Drug classNon-steroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase (COX-1 and COX-2)
ModalitySmall molecule
Therapeutic areaPain Management, Fever, Inflammation
PhaseFDA-approved

Mechanism of action

Metamizole is a non-selective COX inhibitor that decreases prostaglandin production, leading to analgesic, antipyretic, and anti-inflammatory effects. It is a prodrug that is rapidly metabolized to active metabolites in the body. Unlike some other NSAIDs, it has a relatively favorable safety profile in terms of gastrointestinal effects, though agranulocytosis remains a rare but serious concern.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: